News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
751,101 Results
Type
Article (57227)
Company Profile (691)
Press Release (693183)
Section
Business (216776)
Career Advice (2789)
Deals (37400)
Drug Delivery (110)
Drug Development (86386)
Employer Resources (179)
FDA (17564)
Job Trends (15949)
News (369613)
Policy (36931)
Tag
Academia (2907)
Alliances (53254)
Alzheimer's disease (1326)
Approvals (17481)
Artificial intelligence (151)
Bankruptcy (378)
Best Places to Work (12326)
Biotechnology (484)
Breast cancer (139)
Cancer (1191)
Cardiovascular disease (113)
Career advice (2338)
Cell therapy (263)
Clinical research (68340)
Collaboration (426)
Compensation (209)
COVID-19 (2788)
C-suite (107)
Data (1180)
Diabetes (167)
Diagnostics (6579)
Drug pricing (101)
Earnings (88410)
Employer resources (157)
Events (117684)
Executive appointments (329)
FDA (18142)
Funding (384)
Gene therapy (200)
GLP-1 (670)
Government (4866)
Healthcare (20245)
Infectious disease (2881)
Inflammatory bowel disease (119)
Interviews (492)
IPO (17095)
Job creations (4056)
Job search strategy (1969)
Layoffs (468)
Legal (9098)
Lung cancer (186)
Manufacturing (198)
Medical device (14162)
Medtech (14167)
Mergers & acquisitions (20374)
Metabolic disorders (460)
Neuroscience (1635)
NextGen Class of 2024 (7348)
Non-profit (4950)
Northern California (1531)
Obesity (267)
Opinion (227)
Patents (113)
People (59826)
Pharmaceutical (132)
Phase I (21253)
Phase II (29890)
Phase III (22389)
Pipeline (472)
Postmarket research (2992)
Preclinical (9240)
Radiopharmaceuticals (257)
Rare diseases (247)
Real estate (6464)
Regulatory (24393)
Research institute (2596)
Resumes & cover letters (462)
Southern California (1356)
Startups (3949)
United States (14600)
Vaccines (644)
Weight loss (210)
Date
Today (168)
Last 7 days (676)
Last 30 days (3827)
Last 365 days (38222)
2024 (35171)
2023 (42138)
2022 (53493)
2021 (58268)
2020 (57079)
2019 (50276)
2018 (38196)
2017 (35213)
2016 (35181)
2015 (41107)
2014 (34981)
2013 (30229)
2012 (32390)
2011 (32900)
2010 (31039)
Location
Africa (938)
Arizona (214)
Asia (42714)
Australia (7273)
California (3566)
Canada (1323)
China (269)
Colorado (160)
Connecticut (176)
Europe (95673)
Florida (480)
Georgia (129)
Illinois (388)
Indiana (213)
Maryland (632)
Massachusetts (2864)
Michigan (166)
Minnesota (293)
New Jersey (1011)
New York (1009)
North Carolina (824)
Northern California (1531)
Ohio (147)
Pennsylvania (876)
South America (1328)
Southern California (1356)
Texas (521)
Washington State (402)
751,101 Results for "helsinn therapeutics us inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial.
June 24, 2024
·
5 min read
Press Releases
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors
September 20, 2024
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Pharm Country
Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.
April 23, 2024
·
7 min read
Helsinn closes financing agreement with BancaStato to support business objectives and growth
Helsinn Group announces the signing of a new financing agreement with BancaStato, effective from September 2023.
October 10, 2023
·
3 min read
Business
SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers
SOHM, Inc. announces today the collaboration with Coastar Therapeutics, announce their collaboration to advance the field of genome editing using Coastar’s red blood cell membrane derived carriers and SOHM’s ABBIE (A Binding Based Integrase Enzyme) genome editing technology.
April 1, 2024
·
4 min read
Pharm Country
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
Helius Medical Technologies, Inc. announced the completion of site participation enrollment for its stroke registrational program in the U.S. with the addition of REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions.
June 17, 2024
·
10 min read
Press Releases
Evecxia Therapeutics Announces Issuance of a US Patent Covering EVX‑301 in Development for Suicidal Ideation Crisis
November 25, 2024
·
2 min read
FDA
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
Amber Therapeutics, a UK-based medical technology company developing a breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence, announces the successful closing of its Series A financing raising a total of $100 million from leading healthcare and technology investors in the US and UK.
June 10, 2024
·
5 min read
Business
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
G1 Therapeutics, Inc., a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter Bioventures, announced a global licensing agreement for lerociclib for radioprotective uses.
May 22, 2024
·
5 min read
1 of 75,111
Next
